Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) currently has a daily average trading volume of 272.63K but it saw 299303 shares traded on Wednesday. With a market cap of 64.77M USD, stock’s current market price of $1.76 came falling about -9.74 while comparing to the previous closing price of $1.95. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.70 and as low as $1.09. In the recent trading on the day, stock has struck highest price mark of $1.9899 while lowest mark touched by it was $1.75.
Taking a look at 20-day trading activity of Brainstorm Cell Therapeutics Inc. (BCLI) gives us an average price of $2.5040, while its current price level is -62.55% below from 52-week high level whereas it is 62.15% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $3.3073 while that of 200 days or SMA-200 reads an average of $3.1531. A closer look into the stock’s movement over the week reveals that its volatility is standing at 14.80% during that period while stretching the period over a month that decreases to 13.47%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.85 which implies that the stock is in neutral territory.
Brainstorm Cell Therapeutics Inc. (BCLI)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $5.00 and $21.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $5.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $21.00. Average price target assigned by them is $13.00 which highlights an upside potential of 86.46% for the stock over that period. And to attain the median price target of $13.00 assigned by those analysts, stock has to add about 86.46% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 1 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Maxim Group which upgraded the stock as “Buy” in its note to investors issued on February 04, 2021, recommending a price target of $12 for it. Maxim Group issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $5 and $6.
Over the week, BCLI’s stock price is moving 4.76% up while it is -50.35% when we observe its performance for the past one month. Year-to-date it is -56.00% down and over the past year, the stock is showing a downside performance of -40.74%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$0.19 beaten by the consensus estimate of -$0.15 for the same. The company is expected to be releasing its next quarterly report in 03/29/2023, for which analysts forecasted an EPS of -$0.18 while estimate for next year EPS is -$0.71. For BCLI, analysts are forecasting an EPS-growth rate of -4.40% for current year and estimate for EPS growth in next year is 2.80%.
Currently, Brainstorm Cell Therapeutics Inc.’s total number of outstanding shares is 36.49M with 22.57% of that held by the insiders while 10.98% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -236.40%. Stock’s beta reads -0.34. Stock has a price to book (P/B) ratio of 44.00. Its return on asset (ROA) is -116.60% on average.
In the most recent quarter, JPMorgan Funds – Thematics – Gene came cutting its stake by -17.68% in the company and now holds 0.19 million or 0.51% of the company’s stake having worth of about 0.67 million.